Zytiga Becoming a Preferred Treatment for Advanced Prostate Cancer

Revenues from Zytiga (abiraterone acetate), Johnson & Johnson’s drug therapy for advanced prostate cancer, have skyrocketed recently, as countries around the world have adopted it and similar therapies as a preferred early treatment option. Zytiga was originally developed by Cougar Biotechnology, where co-founder Lindsay Rosenwald provided support to the drug’s research team. In 2009, Johnson & Johnson bought the company for almost $1 billion. Now, Zytiga is ushering in a new method of treating prostate cancer that is safe and effective and prolongs the lives of patients in the late stages of the disease. Clinical trials currently are testing abiraterone acetate’s effectiveness on other types of cancer as well.

In late 2012, the U.S. Food and Drug Administration approved abiraterone acetate for pre-chemotherapy use in patients with metastatic castration-resistant prostate cancer (mCRPC). The drug stops the body’s production of estrogen and androgens that can cause cancer to grow. More than 65 countries have approved the use of Zytiga, and the drug is becoming a standard treatment for men with mCRPC.

Advertisements
Explore posts in the same categories: Lindsay Rosenwald

Tags: , , , ,

Responses are currently closed, but you can comment below, or link to this permanent URL from your own site.


%d bloggers like this: